IFN-γ preconditioning of MSCs prior to application has shown promise in animal models of periventricular leukomalacia and experimental autoimmune encephalomyelitis [43, 44] suggesting it might be a good approach to enhance migratory capacity and efficacy of MSC therapy in situations when CXCL10 levels are declining in the brain. This evidence concerns the gene CXCL10 and periventricular leukomalacia.